VALN · Valneva SE

Track VALN — free

$5.81 +0.12 (+2.02%)

Rebalance outlook locked

Market Cap

$539.55M

94.82M

Volume · Oct 9 1676 Avg daily vol (3M) 77.14K

Up next

Next earnings call

Nov 13, 2026 Est · unconfirmed · in 5 wks

Q2 2026 earnings call transcript

call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-48.4%

Trailing year

Short interest

0.2%

Latest settlement · 4.8 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 15, 2026

Emergent BioSolutions: leveraged biodefense name trades like a Narcan story while international MCM mix hits 37%

A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −20%

below

Price vs 50-day avg −9%

below

RSI (14) 35

neutral

MACD trend Negative

52-week position 13%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −15%

trailing

6-month return −5%

trailing

YTD return −35%

this year

Relative strength −14%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $7 — 200d above 50d

Institutional flow Distributing

1 of 20 funds reported for Sep 30 · net -37 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.20% of float · ▼ -1.2% MoM · 4.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

20 holders — mid 3-yr range

Squeeze score 46

elevated · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 65%

annualized · 1-yr

Max drawdown −60%

past year

ATR 4.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−20% Bearish

Price vs 50-day avg

−9% Bearish

RSI (14)

35 Neutral

MACD trend

Negative Bearish

52-week position

13% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $6 › 200d $7 — 200d above 50d

Institutional flow Distributing

1 of 20 funds reported for Sep 30 · net -37 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.20% of float · ▼ -1.2% MoM · 4.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

20 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $5 Now $6 · 13% Range high $12

vs 200-day avg -20% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
VALN Valneva SE this stock	$539.55M	-35.5%	—	—	0.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$127.55B	+11.0%	+46.2%	29.3	1.9%
MRNA Moderna, Inc.	$78.65B	+568.0%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.14B	-4.2%	+20.8%	18.3	2.5%
CSLLY Csl Ltd	$60.24B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 4.0%
Reported: 1 of 20
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

191.8K

Days to cover: 4.8d
Change: -2.3K sh

View

Short Volume

Short vol %

35%

As of: Oct 8, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $273
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

34.6%

Week of: Aug 31, 2026

Off-exch Lit

View

Filings

SEC Filings

Latest

6-K

Filed: Oct 8, 2026
This year: 21

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 16, 2026

Last webcast: Aug 13, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
VALN	-3.6%	-15.0%	-4.5%	-8.0%	-35.5%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	-4.9%	-17.1%	-13.5%	-9.5%	-49.0%

Key facts CIK 1836564 CUSIP 92025Y103 13F (30d) 1 filings 1 filers Visit website Investor relations

VALN · Valneva SE

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Equibles Rating

Technicals

Versus peers

At a glance

Performance